Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$57.31 USD

57.31
4,084,323

-0.42 (-0.73%)

Updated Oct 15, 2024 04:00 PM ET

After-Market: $57.29 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised)

by Zacks Equity Research

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy

by Zacks Equity Research

An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.

Moderna (MRNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $193.24, moving +0.09% from the previous trading session.

Novavax (NVAX) COVID Jab Aids Growth, Overdependence A Woe

by Zacks Equity Research

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Moderna (MRNA) Stock Moves 1.89%: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $193.98, marking a +1.89% move from the previous day.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Donanemab Gets FDA's CRL, MRNA RSV Jab Study Succeeds

by Kinjel Shah

FDA gives CRL to Lilly's (LLY) Alzheimer's candidate, donanemab. Moderna's (MRNA) phase III study on its mRNA-based RSV vaccine candidate in older adults meets primary efficacy endpoints

Novavax (NVAX) Gets Nod for COVID-19 Booster Jab in South Korea

by Zacks Equity Research

Novavax's (NVAX) COVID-19 vaccine gets approval in South Korea as a booster dose in adults 18 years and older.

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RYH

Moderna (MRNA) Soars 3.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Moderna (MRNA) Up on Upbeat Data From Phase III Study on RSV Jab

by Zacks Equity Research

Data from a late-stage study showed that Moderna's (MRNA) RSV vaccine was 83.7% effective at preventing at least two symptoms in adults aged 60 and older.

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?

by Zacks Equity Research

Sector ETF report for RYH

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is First Trust Multi Cap Value AlphaDEX ETF (FAB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FAB

Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More

by Zacks Equity Research

Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.

Moderna (MRNA) Reports 2023 Business View & Pipeline Updates

by Zacks Equity Research

Moderna (MRNA) expects to record a minimum of $5 billion in revenues from COVID vaccine sales in 2023. It also expects to incur around $4.5 billion as R&D expenses in 2023.

Novavax (NVAX) Names John Jacobs as New CEO, Shares Rise

by Zacks Equity Research

Novavax (NVAX) appoints John C. Jacobs as its new president and chief executive officer, effective Jan 23, 2023.

The Zacks Analyst Blog Highlights Thermo Fisher Scientific, Starbucks, Moderna, Canadian Pacific Railway and Micron Technology

by Zacks Equity Research

Thermo Fisher Scientific, Starbucks, Moderna, Canadian Pacific Railway and Micron Technology are included in this Analyst Blog.

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $183.95, moving +2% from the previous trading session.

Sheraz Mian headshot

Top Stock Reports for Thermo Fisher Scientific, Starbucks & Moderna

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), Starbucks Corporation (SBUX) and Moderna, Inc. (MRNA).

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

CytomX (CTMX) Up 55% on Strategic Partnership With Moderna

by Zacks Equity Research

CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.

Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout

by Zacks Equity Research

Moderna (MRNA) inks an agreement to acquire OriCiro for $85 million. The acquisition is expected to expand and boost Moderna's mRNA manufacturing capabilities.

Are Options Traders Betting on a Big Move in Moderna (MRNA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.